Volume 5 Supplement 9
Addition of multiple rare SNPs to known common variants improves the association between disease and gene in the Genetic Analysis Workshop 17 data
© Sykes et al; licensee BioMed Central Ltd. 2011
Published: 29 November 2011
The upcoming release of new whole-genome genotyping technologies will shed new light on whether there is an associative effect of previously immeasurable rare variants on incidence of disease. For Genetic Analysis Workshop 17, our team focused on a statistical method to detect associations between gene-based multiple rare variants and disease status. We added a combination of rare SNPs to a common variant shown to have an influence on disease status. This method provides us with an enhanced ability to detect the effect of these rare variants, which, modeled alone, would normally be undetectable. Adjusting for significant clinical parameters, several genes were found to have multiple rare variants that were significantly associated with disease outcome.
Recent technological advances have made querying the importance of genetic factors on the occurrence of disease severity possible. Hundreds of published studies have acknowledged associations between certain genes and various medical conditions. Newer advances in genotyping technology have allowed researchers to determine even more precisely which genetic base pair may be a marker for the mutation responsible for causing a disease by looking at single-nucleotide polymorphisms (SNPs). SNPs are DNA sequence variations that occur when a single nucleotide (A, T, C, or G) in the genome is altered. Each individual has many SNPs that together create the unique human DNA pattern . These base differences usually have a minor allele frequency (MAF) of 1% or more; SNPs with MAFs less than 1% are known as rare . Previously, because of the popular common disease/common variant hypothesis, which assumes that common diseases are caused by common variants with small to modest effects , and because of the lack of proper technology to accurately genotype rare variants, most association studies have focused on common variants. The near complete 1000 Genomes Project will allow for more accurate genotyping of the so-called rare variants and, as a result, for consideration of rare variants as possible causes of disease .
A change in thought has occurred to increase the importance of rare variants in disease susceptibility . Although several common SNPs have shown significant associations with diseases, these effect sizes have always been small, contributing to the idea that there must be some causal factor in the previously undiscovered rare variants . Several known genetic diseases, such as schizophrenia and type 2 diabetes, have turned up only a few links in the form of the common variants, and it is now thought that common variants could be picking up a diluted signal that is instead caused by neighboring rare variants . Few statistical methods exist for analyzing the role of rare variants, with most methods resulting in low power , and it is imperative to develop new methods to analyze these data. Because the Genetic Analysis Workshop 17 (GAW17) data set is dominated by rare variants (about 74%), the goal of this study is to investigate the potential for combinations of rare variants to strengthen the association between common variants and disease.
The GAW17 data set consists of 24,487 SNPs on 22 chromosomes for 697 unrelated individuals. Thirty percent of the individuals are known to be affected with the disease, and individual quantitative and binary disease traits, Age, Sex, and Smoking status were simulated 200 times. The underlying simulation model is presented by Almasy et al. . We had no knowledge of the genes simulated to be associated with disease outcome when developing and testing our method.
We chose significant clinical parameters by fitting a multivariate logistic regression model with all the possible covariates (Age, Sex, Smoking status, and Ethnicity) and performing backwards selection. Significance was determined by calculating the 95% percentile intervals based on the 200 replicates and choosing only those covariates for which the percentile interval did not include 0.
We first tested for Hardy-Weinberg equilibrium (HWE) in both affected and unaffected populations over all 200 phenotype replicates . An adjusted p-value of 10−5 was used to correct for multiple testing in light of the fact that many of the SNPs are correlated. Those SNPs that failed the HWE test in both subpopulations in at least 95% of the replicates were eliminated from further analysis because these SNPs were thought to be privy to genotyping errors.
Breakdown of number of rare SNPs per gene
Number of rare SNPs
Number of genes
Between 1 and 5
Between 6 and 10
Between 11 and 50
Between 51 and 100
More than 101
For each gene g, we consider common SNPs c j (j = 1, …, n g c ) and rare SNPs r s (s = 1, …, n g r ), where n g c and n g r are the number of common and rare SNPs on gene g, respectively. For all SNPs, we assume a dominant model in which a SNP is coded 1 when a minor allele is present and 0 otherwise. Because of the low frequency of rare SNPs, we thought that the dominant model would provide the best power.
where P = P(Y = 1) and 1cj>0 is a binary indicator variable representing the presence of the minor allele in common SNP c j .. The 200 coefficients β1,1, …, β1,200 are recorded.
If p < 0.05, then adding the rare variants to the common variant significantly increases the signal of the effect of the gene on disease. Therefore these rare variants must be associated with the disease.
If no associations are found, we remove one rare SNP from the definition of Eq. (3) and recalculate the coefficients from Eq. (4) as before. This method is used to determine whether or not no association was detected because of too much noise resulting from the addition of too many rare variants. This method can be generalized through an iterative process by removing one rare SNP at a time until only a single rare SNP remains.
After HWE elimination, we were left with 3,167 genes over the 22 chromosomes. Of these 3,167 genes, 1,718 did not have any common variants or had less than two rare variants and so were excluded from the analysis because this is our primary interest. To eliminate the possibility of adding too much noise by creating a combination of many rare SNPs, we further restricted the analysis to those genes that contained fewer than 16 rare SNPs. Thus we were left with 829 genes to explore.
Adding a combination of rare SNPs to a common SNP significantly increases the signal of association with disease
Number of rare SNPs
2.13 × 10−8
2.13 × 10−8
1.08 × 10−7
2.9 × 10−3
5.12 × 10−9
8.93 × 10−10
5.53 × 10−7
3 × 10−4
6 × 10−4
1.54 × 10−16
1.97 × 10−21
1.01 × 10−25
4.45 × 10−11
2.88 × 10−14
7.27 × 10−10
6.73 × 10−13
5.33 × 10−9
5.04 × 10−12
1.31 × 10−10
8.75 × 10−15
9 × 10−4
4.78 × 10−5
1.5 × 10−4
When one or two rare SNPs were removed from the definition of Eq. (3), some genes that had not been identified by our first pass displayed an increased effect on disease (Table 2, last three rows). This suggests that adding the combination of rare SNPs to a common SNP adds information to the model and helps to better explain the relationship between gene and disease.
Discussion and conclusions
By taking advantage of all 200 phenotype replicates, we were able to simulate a posterior distribution for the underlying true relationship between genes and disease status, thereby inherently validating our method. When working with real data, investigators will not be able to use the replications to calculate p-values. Therefore we can apply the sample randomization technique outlined by Guo et al. . This method has the following steps: (1) Calculate the coefficient for each common variant in each gene from a logistic regression model; (2) shuffle the common SNPs across the genome to generate a permuted data set; (3) calculate the coefficient from a logistic regression between common variant and disease; (4) repeat steps 2 and 3 1,000 times to obtain a null distribution of coefficients; and (5) determine which common variants are significant (at α = 0.1) by calculating the percentage of coefficients from the null distribution that are greater than the observed coefficient. This percentage is our p-value. Finally, adding all the rare SNPs to the common variant, we repeat steps 1–5 to determine which rare SNPs significantly improve the association from the common variant alone.
Although our study focused on binary disease outcome, our method can also be applied to continuous or time-to-event outcomes. The dominant model assumption for the SNPs could also be adjusted to use additive or recessive models. Our method improves on the collapsing method introduced by Li and Leal  by separately considering common variants shown to have disease influence and by adjusting for other factors.
In the interest of time and computational abilities, we limited our analysis to those genes with less than 16 rare SNPs. Important associations may occur in genes with greater than 16 SNPs. In the future it may also be of interest to consider separately those SNPs that are synonymous and nonsynonymous or to include rare SNPs that fall just outside a gene in a larger genomic region in, say, a pathway-based analysis. Our analysis was stopped before considering a maximum removal of two rare SNPs from the combination of all rare SNPs in one gene. A more exhaustive search could uncover new relationships. Our intention was to conduct a proof of principle analysis to exhibit the merits of this method in finding rare SNPs associated with disease.
Gene-based comparison of our method with simulated answers
We would like to thank the organizers of Genetic Analysis Workshop 17 for supplying the data and the Ontario Institute for Cancer Research for funding the internship program. The Genetic Analysis Workshops are supported by National Institutes of Health grant R01 GM031575.
This article has been published as part of BMC Proceedings Volume 5 Supplement 9, 2011: Genetic Analysis Workshop 17. The full contents of the supplement are available online at http://www.biomedcentral.com/1753-6561/5?issue=S9.
- Holmgren Lab: Single nucleotide polymorphism (SNP). [http://groups.molbiosci.northwestern.edu/holmgren/Glossary/Definitions/Def-S/SNP.html]
- Brookes AJ: The essence of SNPs. Gene. 1999, 234: 177-186. 10.1016/S0378-1119(99)00219-X.View ArticlePubMedGoogle Scholar
- Li B, Leal SM: Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet. 2008, 83: 311-321. 10.1016/j.ajhg.2008.06.024.PubMed CentralView ArticlePubMedGoogle Scholar
- Morris A, Zeggini E: An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet Epidemiol. 2010, 34: 188-193. 10.1002/gepi.20450.PubMed CentralView ArticlePubMedGoogle Scholar
- Cirulli ET, Goldstein D: Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev. 2010, 11: 415-425. 10.1038/nrg2779.View ArticleGoogle Scholar
- Almasy LA, Dyer TD, Peralta JM, Kent JW, Charlesworth JC, Curran JE, Blangero J: Genetic Analysis Workshop 17 mini-exome simulation. BMC Proc. 2011, 5 (suppl 9): S2-10.1186/1753-6561-5-S9-S2.PubMed CentralView ArticlePubMedGoogle Scholar
- Wittke-Thompson JK, Pluzhnikov A, Cox NJ: Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet. 2005, 76: 967-986. 10.1086/430507.PubMed CentralView ArticlePubMedGoogle Scholar
- Simon R, Korn EL, McShane LM, Radmacher MD, Wright GW, Zhao Y: Design and analysis of DNA microarray investigations. 2003, New York, SpringerGoogle Scholar
- Guo YF, Li J, Chen Y, Zhang LS, Deng HW: A new permutation strategy of pathway-based approach for genome-wide association study. BMC Bioinform. 2009, 10: 429-10.1186/1471-2105-10-429.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.